Localized FLASH Radiotherapy Reduces Long-Term Skin and Muscle Damage While Preserving Systemic Homeostasis
Giulia FuriniiD, Eduarda Mota‐SilvaiD, Alice UsaiiD, Gaia ScabiaiD, Claudia KusmiciD, Francesco FaitaiD, Andrea Cavalieri, Mariagrazia Celentano, Mario CostaiD, Filippo RossiiD, Giulia Asero, Roberta Di PietroiD, Emanuela GuerraiD, Stefano LattanzioiD, Tonia LucaiD, Sergio CastorinaiD, Roberto CusanoiD, Riccardo BeruttiiD, Jessica Milia, S. CapaccioliiD, Alessandra GonnelliiD, Noemi Giannini, Fabiola PaiariD, Saverio CintiiD, Fabio Di MartinoiD, Margherita MaffeiiD
Abstract
Radiotherapy (RT) is a cornerstone treatment for nearly 50% of cancer patients, but its curative potential and safe dosing are constrained by cumulative toxicity to surrounding healthy tissues. Delivering RT at ultra-high dose rates (FLASH-RT) represents a transformative strategy, as it appears to maintain tumor control, while sparing normal tissue. Melanoma is among the most radioresistant tumors, and skin and muscle are invariably exposed during RT, also in case of deep seated tumors. Here, we compared electron FLASH-RT and conventional RT (CONV-RT) in melanoma-bearing and naive mice assessing tumor control, tissue integrity, and systemic homeostasis over the medium to long term. Both modalities achieved comparable tumor suppression. However, CONV-RT induced persistent skin damage, dermal fibrosis, muscle dysfunction and systemic inflammatory-metabolic alterations, while FLASH-RT largely spared normal tissue and systemic balance. Bulk RNA sequencing revealed striking differences: FLASH induced minimal transcriptional disruption in skin and muscle, whereas CONV-RT triggered thousands of differentially expressed genes, including massive activation of fibrosis, inflammation, cell death-related pathways in skin, and broad dysregulation of genes linked to muscle function, remodeling and the unfolded protein response. Histological and ultrastructural analyses corroborated the findings, showing reduced immune infiltration in the skin and preserved tissue architecture both in skin and muscle following FLASH. In conclusion our study not only confirms the protective nature of FLASH but also provides novel mechanistic insights into the cascade linking local injury to systemic dysfunction under CONV-RT, reinforcing the translational potential of FLASH to expand the therapeutic window of radiotherapy. One Sentence SummaryComparative analysis of FLASH and conventional radiotherapy in a murine model of melanoma and naive mice - Therapeutical efficacy, local and systemic effects.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- FLASH proton reirradiation, with or without hypofractionation, mitigates chronic toxicity in the normal murine intestine, skin, and bone.
Ioannis I. Verginadis, Anastasia P. Velalopoulou, … Theresa M. Busch·Radiotherapy and OncologyPeer-reviewed·Jan 27, 2025
- Effectiveness of FLASH vs conventional dose rate radiotherapy in a model of orthotopic, murine breast cancer
Stavros Melemenidis, Vignesh Viswanathan, … Frederick M. Dirbas·CancersPeer-reviewed·Mar 25, 2025
- Mitochondrial Responses to Conventional and Ultra-high Dose Rate (FLASH) Radiation
Emily G. Caggiano, Maryam E. Elizondo, … Emil Schüler·International Journal of Radiation Oncology*Biology*PhysicsPeer-reviewed·Jul 1, 2026
- Differential impact of FLASH and conventional radiotherapy on a pivotal metabolic organ: White Adipose Tissue
Gaia Scabia, Giulia Furini, … Margherita Maffei·bioRxiv·Apr 1, 2026
- Decrease in dose per fraction impairs the FLASH sparing effect in murine intestine model
Anouk Sesink, R. Geyer, … Veljko Grilj·Radiotherapy and OncologyPeer-reviewed·Nov 3, 2025
- FLASH radiotherapy spares lymphocytes in tumor-draining lymph nodes and increases infiltration of immune cells in tumors
Francisco Sáenz, Brett Velasquez, … Michael T. Spiotto·bioRxiv·Apr 7, 2025